<DOC>
	<DOCNO>NCT01182636</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety test formulation adapalene gel 0.1 % ( PLIVA Research &amp; Development Ltd. ) compare already market formulation , Differin® ( adapalene 0.1 % ) topical gel ( Galderma Laboratories ) patient acne vulgaris .</brief_summary>
	<brief_title>Bioequivalence Adapalene Topical Gel Patients With Acne Vulgaris</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Comparative Clinical Endpoint Studies . Statistical Methods : FDA Bioequivalence Statistical Methods Comparative Clinical Endpoint Studies .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<criteria>Male nonpregnant , nonlactating female , 1240 year age inclusive . Signed informed consent form , meet criteria current FDA regulation . For patient age majority state enrol , patient 's parent legal guardian require sign consent form patient sign IRB approve `` assent participate '' form . If female child bear potential , prepare abstain sexual intercourse use reliable method contraception study ( i.e . condom , Intrauterine device , hormonal contraceptive ) . Patients hormonal contraceptive must hormonal contraceptive 3 month prior baseline visit continue throughout duration study . Have moderate severe facial acne defines : least 20 60 facial inflammatory lesion ( papule pustule ) least 25 100 noninflamed lesion ( open close comedo ) Physician 's Global Assessment score 3 , 4 , 5 . Patient 2 facial nodular lesion , nodule present document included inflammatory lesion count . Patient active cystic acne . Patient acne conglobate . Patient significant facial hair beard tattoo excessive facial scarring , Investigator 's opinion , may interfere evaluation patient 's acne . Patients facial sunburn . Any dermatological condition acne vulgaris , Investigator 's opinion , may interfere evaluation patient 's acne ( e.g . rosacea , psoriasis , dermatitis ) . Females pregnant , lactating , likely become pregnant study . History allergy sensitivity adapalene retinoids , history drug hypersensitivity intolerance , Investigator 's opinion , would compromise safety patient study . Significant history current evidence chronic infectious disease , system disorder , organ disorder , medical condition , Investigator 's opinion , would place study participant undue risk participation . Use topical antibiotic , topical steroid , topical antiinflammatory product use face , oral antibiotic know treat acne , systemic steroid , systemic antiinflammatory agent ( use nonsteroidal antiinflammatory agent ) within 28 day first dose day . Use oral isotretinoin ( Accutane® ) within 6 month . Use topical tretinoin ( RetinA® ) , adapalene ( Differin® ) , tazarotene ( Tazorac® ) , azelaic acid ( Azelex® ) within 28 day first dose day . Receipt drug part research study within 30 day prior dose . Female patient use hormonal contraceptive must type strength hormonal contraceptive least 3 month prior enrollment study throughout duration study . Patients use medicate facial product ( soap , lotion , moisturizers , etc . ) medicate facial cleansing agent 14 day prior study enrollment . Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Acne Vulgaris</keyword>
</DOC>